Prostate Adenocarcinoma Clinical Trials

84 recruitingLast updated: June 17, 2026

There are 84 actively recruiting prostate adenocarcinoma clinical trials across 16 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Chicago, Illinois, United States, Los Angeles, California, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Prostate Adenocarcinoma Trials at a Glance

84 actively recruiting trials for prostate adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in Chicago, Los Angeles, and New York. Lead sponsors running prostate adenocarcinoma studies include Jonsson Comprehensive Cancer Center, Mayo Clinic, and NRG Oncology.

Browse prostate adenocarcinoma trials by phase

Treatments under study

About Prostate Adenocarcinoma Clinical Trials

Looking for clinical trials for Prostate Adenocarcinoma? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 84 trials

Recruiting
Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,524 enrolled98 locationsNCT07200830
Recruiting
Phase 2

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Not Applicable

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Urothelial CarcinomaCervical CarcinomaCutaneous Melanoma+7 more
Institut Claudius Regaud450 enrolled1 locationNCT06967961
Recruiting
Phase 1

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07641049
Recruiting
Not Applicable

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

Prostate Adenocarcinoma
Mayo Clinic10 enrolled1 locationNCT05109208
Recruiting
Phase 2

A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

Prostate CancerProstate Adenocarcinoma
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT07635238
Recruiting
Phase 2

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
University of Utah33 enrolled1 locationNCT05168618
Recruiting
Not Applicable

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Prostate AdenocarcinomaLocalized Prostate Carcinoma
University of California, San Francisco17 enrolled1 locationNCT05665738
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Phase 2

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Prostate Adenocarcinoma
Sean Sachdev50 enrolled1 locationNCT06499870
Recruiting
Phase 2

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Prostate CancerProstate AdenocarcinomaLocalized Prostate Cancer
David Oh68 enrolled2 locationsNCT03821246
Recruiting
Phase 3

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Prostate CancerProstate Adenocarcinoma
Curium US LLC439 enrolled44 locationsNCT06235151
Recruiting
Phase 3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaCastration-Sensitive Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,260 enrolled194 locationsNCT06931340
Recruiting
Phase 2

INSPIRE: INnovative SABR for Prostate Cancer All IREland

Prostate Adenocarcinoma
Cancer Trials Ireland136 enrolled3 locationsNCT07552168
Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting

High-Risk prostatE Cancer radiatiOn Versus surgERy

Prostate CancerProstate Adenocarcinoma
Comprehensive Cancer Centre The Netherlands837 enrolled28 locationsNCT05931419
Recruiting
Not Applicable

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Prostate AdenocarcinomaStage II Prostate Cancer AJCC v8Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Jonsson Comprehensive Cancer Center45 enrolled1 locationNCT07468903
Recruiting
Phase 2

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Prostate CancerProstate Adenocarcinoma
University of California, San Francisco60 enrolled1 locationNCT03933670
Recruiting
Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more
ECOG-ACRIN Cancer Research Group804 enrolled342 locationsNCT04423211
Recruiting
Phase 2

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Prostate Adenocarcinoma
National Cancer Institute (NCI)90 enrolled5 locationsNCT06022822